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Summary
 
Our past studies have shown that the mucosal adjuvant cholera toxin (CT) induces T helper
type 2 (Th2) responses with systemic IgG1, IgE and mucosal secretory IgA (S-IgA) antibodies
(Abs). In this study, recombinant murine IL-12 (rmIL-12) was given either parenterally or
orally to mice orally immunized with tetanus toxoid (TT) and CT to determine whether this
cytokine could redirect the CT-induced Th2-type responses and what effect this shift would
have on S-IgA Ab responses. Intraperitoneal administration of rmIL-12 shifted TT-specific re-
sponses toward Th1-type and resulted in CD4
 
1
 
 T cells producing IFN-
 
g
 
 and IL-2 with mark-
edly reduced levels of Th2-type cytokines. This cytokine profile was accompanied by increased
delayed-type hypersensitivity (DTH) and shifts in serum IgG1 to IgG2a and IgG3 anti-TT Ab
responses. Further, serum IgE and S-IgA Ab responses were markedly reduced by parenteral
IL-12. When IL-12 complexed to liposomes was given orally both shifts to IgG2a and IgG3
and low IgE Abs again occurred concomitant with enhanced serum IFN-
 
g
 
 and DTH re-
sponses. Interestingly, oral rmIL-12 did not result in significant levels of serum IL-12 nor al-
tered S-IgA Ab responses and resulted in higher levels of some Th2-type cytokines both in
vitro and in vivo when compared with parenteral IL-12. Our results show that the shifts in sys-
temic immune responses with intact S-IgA Abs which occur after oral delivery of IL-12-lipo-
somes are due to cytokine effects in the Peyer’s patches and suggest new strategies for the tar-
geted manipulation of Th1- and Th2-type responses to mucosal vaccines.
 
I
 
L-12, a 40 (p40) and 35 (p35) kD dimeric molecule, ex-
hibits remarkable regulatory effects on NK and T cells
for enhanced production of IFN-
 
g
 
 (1–4). As a product of
macrophages and other APC (5–8), IL-12 appears to set the
stage for effective helper type 1 T cell responses which re-
sult in IFN-
 
g
 
 production and subsequent cell-mediated
immunity (CMI)
 
1
 
 (4, 6, 9–15). A major in vivo effect of
IL-12 has been to enhance both NK and CTL lytic activity
(1, 16–19). In this regard, IL-12 was shown to restore CMI
responses in the peripheral blood of HIV
 
1
 
 individuals (20).
One could envision two IL-12 effects, e.g., the initial pro-
motion of Th1-type responses from naive T cell precursors
(4, 6), or a reversal of an established Th2-type response by
initiation of Th1-type responses (21), and evidence for both
pathways has been put forth. The precise mechanisms in-
volved in preferential induction of Th1-type responses and
for down regulation of Th2-type responses are still unknown.
It is now well established that selected cytokines from
Th1- or Th2-type cells can downregulate the expression of
the opposite Th cell phenotype (22–24). For example,
IFN-
 
g
 
 production by Th1 cells down regulates IL-4, a ma-
jor cytokine expressed by Th2 cells, and conversely IL-4
(with IL-10) effectively diminishes IFN-
 
g
 
 production by
CD4
 
1
 
 Th1 cells (22–25). Because the in vivo network of
Th1- and Th2-type cytokines can determine the profile of
antibodies produced during an immune response (26), the
biased induction by IL-12 of Th1-type responses would be
 
1
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9
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expected to influence the isotype of antigen-specific anti-
body responses. In this regard, IL-12 can inhibit produc-
tion of IgE antibodies, both in vitro (27) and in vivo (15,
28); however, the effects of IL-12 for IgG subclass re-
sponses are less clear (15, 28–30). Although IL-12 is con-
sidered to be a potent regulatory molecule for systemic im-
mune responses, to our knowledge, no previous study has
evaluated the effects of IL-12 on secretory IgA (S-IgA) re-
sponses.
Past studies by our group have used the well character-
ized vaccine protein tetanus toxoid (TT) and the mucosal
adjuvant cholera toxin (CT). In this system, co-oral admin-
istration of TT and CT to C57BL/6 mice induces CD4
 
1
 
Th2-type cells in both mucosal (Peyer’s patches [PP]) and
systemic (spleen) lymphoid tissues (31, 32). This immuniza-
tion regimen induced brisk antigen-specific mucosal S-IgA
Abs together with serum IgG1 (and IgG2b), and IgA Ab
responses to TT (32, 33). Furthermore, we (32) and others
(34) have shown that CT also induces systemic IgE re-
sponses, and the immune responses which are triggered by
CT as mucosal adjuvant are dependent upon IL-4 and
Th2-type responses (31, 32, 35).
The current study was undertaken to determine if par-
enterally administered IL-12 could alter mucosal and pe-
ripheral immune responses induced by TT and CT as adju-
vant, and redirect Th2-type responses toward Th1-type
development. We also queried if it would be possible to
deliver IL-12 by a mucosal (e.g., oral) route in order to in-
fluence the balance of Th1- and Th2-type responses.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free C57BL/6 mice were used
throughout this study. The mice were initially obtained from the
Frederick Cancer Research Facility (National Cancer Institute,
Frederick, MD), and during the past year from the Charles River
Laboratories (Wilmington, DE). All mice were received at 5–6
wk of age and were maintained in horizontal laminar flow cabi-
nets in sterile caging conditions of the animal facility provided by
the UAB Immunobiology Vaccine Center. The mice were free
of bacterial and viral pathogens as determined by routine Ab
screening and by histologic analysis of major organs and tissues.
The mice were used at 8–12 wk of age in all experiments de-
scribed here.
 
Oral Immunization and Treatment with Recombinant Murine IL-12.
 
Before oral immunization, groups of mice were deprived of food
for 2 h, followed by intragastric administration of an isotonic bi-
carbonate solution (8 parts HBSS and 2 parts 7.5% sodium bicar-
bonate) to neutralize stomach acidity (31–33). Individual mice
were gavaged with a 0.25 ml phosphate-buffered saline solution
(PBS, pH 7.2) containing vaccine grade TT (250 
 
m
 
g/mouse),
which was kindly provided by Dr. Patricia J. Freda Pietrobon
(Connaught Laboratories, Inc., Swiftwater, PA). CT was given
(10 
 
m
 
g/mouse) (LIST Biologic Laboratories, Campbell, CA) as
mucosal adjuvant. Groups of 5–7 mice were orally immunized
with TT plus CT on days 0, 7, and 14 and fecal pellets and blood
samples collected as previously described (32, 33).
Recombinant murine IL-12 (rmIL-12) was generously pro-
vided by Dr. Maurice K. Gately (Hoffmann-LaRoche, Nutley,
NJ) and was given in various doses to mice by the i.p. or oral
route (see Fig. 1). For i.p. delivery, rmIL-12 (10, 100, or 1000
ng/dose) was diluted in sterile PBS containing 1% normal mouse
serum and given daily (5 times/wk) as indicated in Fig. 1. For
oral delivery, rmIL-12 (1,000 ng/dose) was complexed with pre-
formed cationic liposomes (DOTAP; Boehringer Mannheim Corp.,
Indianapolis, IN). Preliminary experiments established that ad-
ministration of liposomes alone did not affect immune responses
to the vaccine and that rmIL-12 complexed to DOTAP lipo-
somes retained its biologic activity in vitro and in vivo. More-
over, dose-response experiments established that optimal liposome
uptake of rmIL-12 was obtained at a 50:1 ratio (wt/wt) of DOTAP
liposome mixed with IL-12. Mice receiving oral DOTAP-IL-12
(liposome-IL-12) were deprived of food for 2 h followed by neu-
tralization of stomach acidity as described above. On days where
mice were given oral liposome-IL-12 and TT with CT, two sep-
arate gavages were made first with oral TT plus CT followed by
oral liposome-IL-12 at an 
 
z
 
30 min interval (Fig. 1).
 
Analysis of Antibody Isotypes and IgG Subclasses.
 
An ELISA was
used to titrate antibody levels in serum and fecal extracts (32, 33).
The extracts from fecal pellets were prepared as described else-
where (32, 33). In brief, 0.1 g of pellet was mixed with 1 ml of
PBS containing 0.1% NaN
 
3
 
 and vortexed for 5–10 min. After
centrifugation, supernatants were collected and stored at 
 
2
 
70
 
8
 
C
until assayed for TT-specific Abs. For assays, plates (Microtest III;
Becton Dickinson, Oxnard, CA) were coated with a 100 
 
m
 
l solu-
tion of TT (5 
 
m
 
g/ml; 1.25 Lf U/ml) and serial twofold dilutions
of serum or fecal extracts added to individual wells. Titers of IgM,
IgG or IgA were determined by addition of a 1:2,000 dilution of
HRP-conjugated goat anti–mouse 
 
m
 
, 
 
g
 
, or 
 
a
 
 heavy chain specific
antisera (Southern Biotechnology Associates [SBA], Inc., Bir-
mingham, AL). To determine IgG subclass titers, 100 
 
m
 
l of biotin
conjugated, rat monoclonal anti–mouse 
 
g
 
1 (G1-7.3; 2 
 
m
 
g/ml),
 
g
 
2a (R19-15; 1 
 
m
 
g/ml), 
 
g
 
2b (R12-3; 0.5 
 
m
 
g/ml), or 
 
g
 
3 (R40-82;
1 
 
m
 
g/ml) heavy chain–specific antibodies were used (PharMin-
gen, San Diego, CA) as described previously (32). After incuba-
tion and washing steps, a 100-
 
m
 
l aliquot of HRP-conjugated strep-
tavidin (GIBCO BRL, Gaithersburg, MD) was added and color
developed with 3,3
 
9
 
,5,5
 
9
 
-tetramethylbenzidine (TMB) substrate
(Moss Inc., Pasadena, MD). The color reaction was terminated
after 15 min with 50 
 
m
 
l of 0.5 N HC1 and absorbance at 450 nm
was determined with an ELISA plate reader. Data were expressed
as reciprocal endpoint titers of the last dilution exhibiting an opti-
cal density of 
 
>
 
0.1 when compared with negative controls.
Total IgE levels and antigen-specific IgE Ab titers were deter-
mined by a sensitive ELISA and a passive cutaneous anaphylaxis
(PCA) assay, respectively, as previously described (32). For total IgE
measurements, Nunc-Immuno-MaxiSorp plates were coated with
2 
 
m
 
g/ml of rat monoclonal anti-mouse IgE antibody (R35-72;
PharMingen). Serial dilutions of immune serum or standard mouse
IgE (PharMingen) were then added followed by addition of 100 
 
m
 
l
of a biotinylated rat monoclonal anti-mouse IgE antibody (R35-
92; PharMingen). The HRP-conjugated streptavidin described
above was used for detection and plates were then developed
with the TMB substrate. The PCA test was performed to deter-
mine titers of TT-specific IgE antibodies. Fisher rats (200–250 g)
were sensitized by injecting threefold dilutions of mouse sera
(starting at 1:10) into their shaved back. After 16 h, the rats re-
ceived an i.v. injection of 200 
 
m
 
g of TT in 1 ml of 1% Evan’s
blue dye in PBS. The rats were killed 15 min later and the diam-
eter of blueing resulting from the localized degranulation of mast
cells was determined. The end-point titer was selected as the last
dilution resulting in a diameter of blueing of 
 
>
 
5 mm.
 
B Cell Enzyme-linked Spot for IgA Antibody-forming Cells.
 
An 
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enzyme-linked spot (ELISPOT) assay was used to quantitate num-
bers of IgA antibody-forming cells (AFC) present in the lamina
propria (LP) of the small intestine of mice orally immunized with
TT and CT either in the presence or absence of IL-12. The LP
cells, isolated as previously described (33, 36), were 
 
.
 
95% viable
as determined by trypan blue dye exclusion, and were resus-
pended in complete medium (RPMI 1640; Cellgro Mediatech,
Washington, DC) containing 10% FCS, 2 mM 
 
l
 
-glutamine, 1 mM
sodium pyruvate, 10 mM Hepes, 100 U/ml penicillin and 100
 
m
 
g/ml streptomycin. Antigen-specific IgA AFC were then deter-
mined in LP cell suspensions by TT-specific ELISPOT assay as
described previously (33, 36). In brief, 96-well nitrocellulose-
based plates were coated with a 100-
 
m
 
l solution of TT (5 
 
m
 
g/ml)
diluted in PBS and control wells received PBS without TT. The
wells were blocked with 1% BSA in PBS. Serial fivefold dilutions
(starting at 1 
 
3
 
 10
 
6
 
 cells) were added to the wells in duplicate and
incubated for 6 h. Individual AFC were detected with peroxi-
dase-labeled anti-mouse 
 
a
 
 chain–specific antibodies (1 
 
m
 
g/ml) (SBA)
and were visualized by adding the chromogenic substrate, 3-amino-
9-ethylcarbazole (AEC) (Moss Inc.). Individual AFC were counted
with the aid of a dissecting microscope (SZH Zoom Stereo Mi-
croscope System; Olympus, Lake Success, NY).
 
In Vivo Delayed-type Hypersensitivity Responses.
 
The delayed-
type hypersensitivity (DTH) responses were assessed in mice that
received oral TT and CT as adjuvant in the presence or in the ab-
sence of rmIL-12. 20 
 
m
 
g of TT in 20 
 
m
 
l of sterile PBS (1 mg/ml)
was injected into the left ear pinna as described in our previous
study (36). The right ear pinna received sterile PBS as a control or
an unrelated antigen (OVA). Ear swelling was measured 24 and
48 h later with a spring-loaded dial thickness gauge (Starrett Co.,
Athol, MA). Positive DTH responses were expressed as an in-
crease in ear swelling (in 
 
m
 
m) in TT-injected sites after subtrac-
tion of swelling of the control site.
 
Assessment of Antigen-specific CD4
 
1
 
 T Cell Responses.
 
Single-cell
suspensions of PP and spleen (SP) from immunized and control
mice were obtained as previously described (31, 32). In brief, in-
dividual PP were excised and individual cells were dissociated by
incubation in Joklik’s medium containing Dispase
 
Ò
 
 (1.5 mg/ml)
(Boehringer-Mannheim Corp.). A total of 4–6 treatments were
required for complete cell removal, and dissociated cells were ex-
tensively washed in incomplete RPMI 1640 medium to remove
excess Dispase
 
Ò
 
. The isolated PP cells were incubated in com-
plete medium (2–4 h) to allow de novo re-expression of mem-
brane proteins. SP cell suspensions were obtained by teasing small
fragments through sterile wire screens, and single cells were ob-
tained from the supernatant after 1
 
3
 
 gravity settling. Enriched
CD4
 
1
 
 T cells were obtained from PP and SP cell preparations by
panning on anti-L3T4 (GK 1.5) mAb coated petri dishes as de-
scribed elsewhere (31, 32). Two cycles of panning resulted in
CD4
 
1
 
 T cell-enriched cultures which were 
 
.
 
97% CD3
 
1
 
,
CD4
 
1
 
, and CD8
 
2
 
 and were 
 
.
 
99% viable.
For the stimulation of Ag-specific CD4
 
1
 
 T cells in vitro, TT
or OVA was adsorbed to latex microspheres as described previ-
ously (31, 32, 36–39) and CD4
 
1
 
 T cells were restimulated in
vitro according to previously described methods (31, 32). In brief,
CD4
 
1
 
 T cells (2 
 
3
 
 10
 
6
 
 cells/ml) were cultured with rIL-2 (10 U/ml,
PharMingen), and T cell–depleted, irradiated (3,000 R) feeder
SP cells from naive mice in flat-bottom 96-well (200 
 
m
 
l/well) or
24-well (1 ml/well) tissue culture plates (Corning Glass Works,
Corning, NY) for proliferation and cytokine synthesis, respec-
tively. To measure antigen-specific T cell proliferation, 0.5 
 
m
 
Ci of
tritiated [
 
3
 
H]thymidine (Amersham Corp., Arlington Heights, IL)
was added after 6 d of culture and 18 h before harvest. Approxi-
mately 10 TT-coated particles/cell were found to optimally stim-
ulate CD4
 
1
 
 T cell cultures based on the extent of cellular prolif-
eration as well as levels of cytokines produced in culture
supernatants. For the assessment of cytokine production, culture
supernatants were harvested after 6 d of incubation. Control wells
consisted of cells only or cells incubated with unabsorbed beads
or OVA-coated beads. All cell cultures were maintained at 37
 
8
 
C
in a 5% CO
 
2
 
 incubator in moist air.
 
Cytokine ELISA.
 
Cytokine levels in culture supernatants and
sera were determined by ELISA using the appropriate combina-
tion of mAbs described in our previous study (36). In brief, Fal-
con Microtest III plates (Becton Dickinson) were coated with
100 
 
m
 
l of anti-cytokine Ab diluted in 0.1 M bicarbonate buffer
(pH 8.2) and incubated overnight at 4
 
8
 
C. The wells were blocked
with PBS containing 1% BSA at room temperature for 1 h. Serial
twofold dilutions of supernatants or sera were added to duplicate
wells and incubated overnight at 4
 
8
 
C. The wells were then
washed with PBS-Tween (PBS-T) and incubated with the ap-
propriate biotinylated anti-cytokine mAb diluted in PBS-T with
1% BSA for 1 to 2 h. After three rinses, wells were incubated
with peroxidase-labeled anti-biotin Ab (0.5 
 
m
 
g/ml; Vector Labo-
ratories, Inc., Burlingame, CA) for 1 h and developed with TMB
reagent (Moss, Inc.). Standard curves were generated using mu-
rine rIFN-
 
g
 
, rIL-5, rIL-6, and rIL-10 (Genzyme, Cambridge,
MA); rIL-2 (PharMingen); and rIL-4 (Endogen, Boston, MA).
The ELISA assays were capable of detecting 15 pg/ml for IFN-
 
g
 
,
5 pg/ml for IL-2, IL-4, and IL-5, 100 pg/ml for IL-6 and 200
pg/ml for IL-10. Serum IL-12 levels were measured by using a
combination of antibodies (for coating and detection) kindly pro-
vided by Dr. David H. Presky (Hoffman-LaRoche).
 
Statistics.
 
The results are expressed as the mean 
 
6
 
 one stan-
dard deviation. Statistical significance (
 
P
 
 
 
,
 
0.05) was analyzed by
Student’s 
 
t
 
 test and by ANOVA followed by Fisher least signifi-
cant difference test. For statistical analysis of cytokine levels, those
below the detection limit were recorded as one-half the detection
limit (e.g., IFN-
 
g
 
 
 
5
 
 7.5 pg/ml).
 
Results
 
Parenteral rmIL-12 Downregulates Serum IgE and Shifts IgG
Subclasses in Response to an Oral Vaccine.
 
Since IL-12 plays
an important role in the induction of IFN-
 
g production
and subsequent Th1-type responses, we queried whether
IL-12 treatment would alter Th2-type responses and the
resultant serum IgE and IgG subclass responses in mice re-
ceiving oral TT plus CT as adjuvant (31, 32, 40, 41). Fre-
quent i.p. injections of rmIL-12 downregulated both poly-
clonal and TT-specific IgE Abs (see Fig. 2 A). The effect of
rmIL-12 was dose dependent because IgE responses were
not significantly affected by administration of 10 ng of
rmIL-12, while a significant decrease in both polyclonal
and TT-specific IgE Abs was observed in mice receiving
100 ng/dose (see Fig. 2 A). The distribution of anti-TT
IgG subclass Ab responses was also affected by parenteral
rmIL-12 treatment and small increases in IgG2a anti-TT
Abs were observed in mice given a 10 ng/dose of rmIL-12
(see Fig. 2 B). When the dose of rmIL-12 was increased to
100 ng, a significant change in the profile of IgG subclasses
was observed with concomitant down regulation of IgG1
and increases in IgG2a and IgG3 Ab titers. Despite this shift418 Oral IL-12 Redirects Th2®Th1 with IgA Responses
in IgG subclass distribution, serum TT-specific IgG, IgA,
and IgM titers were similar in mice orally immunized with
TT plus CT in the presence or in the absence of IL-12,
suggesting that rmIL-12 did not affect the potency of CT as
adjuvant for serum Ab responses (see Fig. 2 C). Antibody
responses of all isotypes were abrogated in mice receiving
1,000 ng/dose of rmIL-12, indicating that high doses of
rmIL-12 impaired the ability of CT to act as a mucosal ad-
juvant (results not shown). However, z40% of mice which
received 10–14 doses of 1,000 ng of rmIL-12 did not sur-
vive, perhaps due to combined toxic effects of CT and
IL-12.
Oral IL-12-Liposome Effects on Systemic Ab Responses to an
Oral Vaccine. We next determined if rmIL-12 could be
given by the oral route. To obviate potential degradation in
the gastrointestinal (GI) tract, mice were given 1,000 ng of
rmIL-12/dose complexed to liposomes. The efficacy of oral
rmIL-12-liposomes was assessed in two schedules, both of
which included the time of oral immunization (Fig. 1),
since it has been shown that shifts toward Th1-type re-
sponses require IL-12 delivery at the time of antigen ad-
ministration (15, 42). Analysis of serum IgE responses in
mice orally immunized with TT plus CT and receiving
oral rmIL-12–liposomes showed that three doses (days 0, 7,
and 14) of rmIL-12 significantly downregulated both poly-
clonal and TT-specific IgE responses, an effect which was
further increased when six oral doses (days 0, 3, 7, 10, 14,
and 17) of rmIL-12–liposomes were given (Fig. 3 A). Ad-
ministration of three doses of rmIL-12 also resulted in
moderate increases in serum IgG2a and IgG3 anti-TT Ab
responses (see Fig. 3 B); however, six oral doses of rmIL-12–
liposomes elicited high IgG2a and IgG3 anti-TT Ab titers
and downregulated TT-specific IgG1 Ab responses (see
Fig. 3 B). Interestingly, the inhibition of serum IgE re-
sponses and the changes in IgG subclass responses after ad-
ministration of six oral doses of rmIL-12–liposomes (1,000
ng/dose) were comparable to or greater than those ob-
served after parenteral rmIL-12 (100 ng/dose) (Fig. 2). De-
spite the effects of rmIL-12 on IgG subclass responses, the total
levels of serum IgG, IgM and IgA were not significantly af-
fected by oral administration of this cytokine (Fig. 3 C).
Parenteral Versus Oral rmIL-12 Delivery Have Different Ef-
fects on Mucosal IgA Responses. We next compared the ef-
fect of rmIL-12 given i.p. or orally on TT-specific mucosal
IgA Ab responses to oral TT plus CT as adjuvant. Three
oral doses of TT with CT at weekly intervals led to brisk
fecal IgA Abs and elevated numbers of IgA anti-TT AFC
in isolated lamina propria lymphocytes (LPLs) (Fig. 4, A
and B). Intraperitoneal delivery of rmIL-12 resulted in an
eightfold decrease in IgA Ab titers, which correlated with
an z50% reduction in IgA AFC in isolated LPLs (Fig. 4, A
and B). In sharp contrast to the significant inhibition of
mucosal IgA anti-TT Ab responses induced by parenteral
rmIL-12, neither IgA anti-TT Abs nor numbers of IgA
AFC in isolated LPLs were affected by oral delivery of
rmIL-12 (Fig. 4, A and B). Thus, both oral and parenteral
rmIL-12 reduced IgE responses and induced shifts from
IgG1 to IgG2a and IgG3 anti-TT Ab responses in serum,
Figure 1. rmIL-12 treatment
schedules for mice which re-
ceived a combined oral vaccine.
Four groups of C57BL/6 mice
were given TT plus CT as adju-
vant on days 0, 7, and 14 by the
oral route. Group A were posi-
tive controls receiving oral vac-
cine but not rmIL-12. Group B
received 15 doses of rmIL-12
(day 0 to 5, 7 to 11, and 14 to
18) by the intraperitoneal route.
This group was subdivided into
mice receiving 10, 100, or 1,000
ng of rmIL-12/dose. Groups C
and D received three (days 0, 7,
14) or six (days 0, 3, 7, 10, 14,
17) oral doses of rIL-12 com-
plexed to liposomes.419 Marinaro et al.
while only the oral route of delivery allowed mucosal IgA
anti-TT Ab responses.
Cytokine Profiles of TT-specific CD41 T Cells of Mice Given
Combined Oral Vaccine and rmIL-12. It was important to
determine cytokine profiles exhibited by TT-specific CD41
T cells from both peripheral (SP) and mucosal (PP) im-
mune compartments since mice treated parenterally or
orally with rmIL-12 exhibited comparable effects on serum
Ab responses but different effects on mucosal IgA Ab re-
sponses. Culture supernatants from PP and SP CD41 T cells
restimulated with Ag in vitro revealed that T cells from
mice treated either orally or parenterally with rmIL-12 se-
creted more IFN-g than did T cells from mice orally im-
munized with TT and CT only (Fig. 5 A). The two differ-
ent treatment routes both led to induction of comparable
IFN-g synthesis at the mucosal level (PP) and in SP. IL-12
treatment also increased IL-2 secretion by splenic T cells
and to a lesser extent by PP T cells. Levels of IL-4, IL-5,
IL-6, and IL-10 assessed in culture supernatants of TT-spe-
cific CD41 T cells from SP and PP were significantly
downregulated after parenteral administration of rmIL-12
(Fig. 5 B). Oral rmIL-12–liposomes downregulated IL-4
secretion but reduced IL-5, IL-6, and IL-10 secretion by
SP and PP CD41 T cells less markedly (Fig. 5 B).
Effects of Oral and Parenteral IL-12 on Serum Cytokine Lev-
els. To directly compare the in vivo effects of oral or i.p.
delivery of rmIL-12, we measured serum cytokine levels
(IL-2, IFN-g, IL-4, IL-5, IL-6, and IL-10) in mice that re-
ceived the oral vaccine and oral or parenteral rmIL-12.
While serum IL-2 and IFN-g were undetectable in mice
Figure 2. The effect of par-
enteral administration of rmIL-12
on polyclonal and TT-specific se-
rum Ab responses in mice orally
immunized with TT and CT as
mucosal adjuvant. Mice received
the oral vaccine alone (unshaded)
or together with rmIL-12 by the
i.p. route (shaded, 10 ng/dose or
striped, 100 ng/dose). (A) Poly-
clonal and TT-specific serum IgE
Abs were measured on day 14 by
ELISA and PCA assays, respec-
tively. (B) The distribution of
TT-specific serum IgG subclasses
were analyzed on day 21 by
ELISA. (C) Serum TT-specific
IgM, IgA, and IgG Abs were
measured by ELISA on day 21.
Results are expressed as the
mean  6 one SD from three dif-
ferent experiments (five mice per
group).420 Oral IL-12 Redirects Th2®Th1 with IgA Responses
receiving the oral vaccine alone, i.p. delivery of 100 ng/
dose of rmIL-12 induced high levels of serum IFN-g (Fig.
6 A). Interestingly, oral administration of rmIL-12–lipo-
somes (6 doses; 1,000 ng/dose) also resulted in significant
serum IFN-g levels in mice orally immunized with TT
plus CT as adjuvant; however, systemic rmIL-12 induced
the highest levels of serum IFN-g (Fig. 6 A). When serum
IL-4, IL-5, IL-6 and IL-10 levels were assessed in the three
Figure 3. The effect of oral
administration of rmIL-12 on
polyclonal and TT-specific se-
rum Ab responses. Mice received
the oral combined vaccine alone
(unshaded) or vaccine together
with rmIL-12 complexed to li-
posomes by the oral route
(striped, 1,000 ng/dose three
times and shaded, 1,000 ng/dose
six times). (A) Polyclonal and
TT-specific serum IgE Abs were
measured on day 14 by ELISA
and PCA assays, respectively. (B)
The distribution of TT-specific
serum IgG subclasses were deter-
mined on day 21 by ELISA. (C)
Serum TT-specific IgM, IgA,
and IgG Abs were measured by
ELISA on day 21. Results are
expressed as the mean 6 one SD
from four different experiments
(five mice per group).
Figure 4. The effect of oral and parenteral ad-
ministration of rmIL-12 on mucosal IgA responses
to an oral vaccine consisting of TT and CT as mu-
cosal adjuvant. TT-specific S-IgA Ab titers in fecal
extracts were measured on day 21 by ELISA. The
frequency of TT-specific IgA AFCs in LPLs was
determined on day 21 by ELISPOT. Mice received
the oral vaccine alone (unshaded) or together with
rmIL-12 by i.p. injection (striped, 100 ng/dose) or
six oral administrations (shaded, 1,000 ng/dose). The
results are expressed as the mean 6 one SD from
four different experiments (five mice per group).421 Marinaro et al.
different mouse groups, oral TT and CT as adjuvant in-
duced high levels of IL-5 and IL-10 (Fig. 6, B and C),
while both IL-4 and IL-6 were undetectable in all groups
tested (data not shown). Serum IL-5 and IL-10 levels were
significantly decreased in mice receiving parenteral IL-12
(Fig. 6 B), while mice fed oral IL-12–liposomes exhibited
higher levels of both IL-5 and IL-10. These findings again
show that the route of rmIL-12 delivery affects the pattern
of cytokines secreted in vitro and in vivo.
Both Oral and Parenteral IL-12 Induce DTH Responses.
To assess changes in CMI responses resulting from the shift
in cytokine production, we measured DTH responses to
TT in mice orally or parenterally treated with rmIL-12. Mice
given the combined oral vaccine alone did not develop sig-
nificant DTH responses, supporting the presence of a pre-
dominant Th2-type immune response (Fig. 7). In contrast,
mice treated either orally or parenterally with rmIL-12 dur-
ing the immunization protocol exhibited significantly higher
Figure 5. The induction of
Th1-type (IL-2 and IFN-g) and
Th2-type (IL-4, IL-5, IL-6, and
IL-10) cytokine secretion by
CD41 T cells isolated from mu-
cosally immunized mice which
had been given oral (shaded) or
parenteral (striped) rmIL-12. SP
and PP CD41 T cells, were puri-
fied from mice receiving the
combined oral vaccine only (un-
shaded) or combined vaccine to-
gether with rmIL-12 orally (six
times, 1,000 ng/dose) or par-
enterally (15 times, 100 ng/dose)
and were restimulated in vitro
for 6 d in the presence of feeder
cells and TT-coated beads. Th1-
type (A) and Th2-type (B) cy-
tokine production in culture su-
pernatants were analyzed by
ELISA. Cytokine levels are rep-
resentative of three separate ex-
periments.422 Oral IL-12 Redirects Th2®Th1 with IgA Responses
DTH responses 24 h after TT challenge when compared
with mice receiving the oral vaccine and adjuvant only.
Kinetics of Serum IL-12 After Parenteral or Oral Administra-
tion of rmIL-12. We also determined if the effect of oral
IL-12 was due to the passage of the cytokine into the pe-
riphery or was due to a localized action in the GI tract. To
this end, we measured serum IL-12 levels at different time
points after oral (1,000 ng) or intraperitoneal (10, 100, and
1,000 ng) administration of rmIL-12. No detectable levels
of IL-12 were found in sera before administration of this
cytokine (Table 1); however, mice which received rmIL-12
by the i.p. route exhibited serum IL-12 by 30 min, and lev-
els were maintained over a 2-h interval, and then gradually
decreased over the next 48 h (Table 1). The serum concen-
tration of IL-12 after intraperitoneal administration was
dose dependent and increasing doses prolonged the survival
of cytokine in the circulation. On the other hand, mice re-
ceiving rmIL-12 by the oral route exhibited negligible lev-
els of serum IL-12 which peaked 2 h after administration
and had markedly decreased by 24 h. These results sug-
gested that the effects of oral IL-12 on the immune re-
sponse to the vaccine did not result primarily from the pas-
sage of the cytokine into the circulation. Furthermore, oral
administration of CT did not alter either the kinetics or the
amount of serum IL-12 detected in mice receiving either
oral or parenteral IL-12.
Discussion
CT has been the most widely used mucosal adjuvant to
induce mucosal S-IgA and parenteral immune responses to
coadministered proteins in experimental animals (43) and
our recent studies have shown that Th2-type responses to
coadministered protein antigens are responsible for the iso-
type and subclass of Ab response when CT is used as adju-
vant (31, 32). The major findings of the present study are
that oral as well as parenteral administration of rmIL-12 re-
directs the CT-induced Th2 cell–mediated responses to
IFN-g producing Th1 cells with enhanced DTH and se-
rum IgG2a and reduced IgE Ab responses. However, oral de-
livery of rmIL-12 complexed to liposomes, unlike parenteral
rmIL-12 did not impair mucosal S-IgA Ab responses. The
effects of IL-12 on induction of Th1-type and suppression
of Th2-type responses are well documented (21, 42, 44,
45); however, no previous studies have addressed the effect
of this cytokine on mucosal S-IgA responses or the possi-
bility of its mucosal (e.g., oral) delivery. Therefore, we in-
vestigated the role of IL-12 in a model which purposely
Figure 6. The induction of Th1-type (IFN-g) and Th2-type (IL-5 and IL-10) cytokines in sera of mice receiving rmIL-12 and orally immunized with
TT and CT as adjuvant. Mice received the combined oral vaccine (unshaded) together with rmIL-12 by the i.p. route (striped, 15 times, 100 ng/dose) or
by the oral route (shaded six times, 1,000 ng/dose). Levels of IFN-g, IL-5, and IL-10 in the serum were determined on day 21 by ELISA. The results are
expressed as the mean 6 one SD and are representative of three different experiments.
Table 1. Kinetics of Serum IL-12 after Intraperitoneal or Oral Administration*
Route of IL-12
administration
Dose of
IL-12 (ng)
Serum IL-12 levels (ng/ml)
0 min 30 min 2 h 24h 48 h
Intraperitoneal 10 ,0.05 0.496 0.384 ,0.05 ,0.05
Intraperitoneal 100 ,0.05 10.4 8.8 3.9 0.42
Intraperitoneal 1000 ,0.05 93.7 86.5 56.3 6.1
Oral 1000 ,0.05 ,0.05 0.175 0.079 ,0.05
*Groups of C57BL/6 mice received 10, 100, or 1,000 ng of rmIL-12 by the intraperitoneal or 1,000 ng of rmIL-12 by the oral route. Sera were col-
lected at different intervals and IL-12 levels were measured by an IL-12-specific ELISA. Results are representative of three separate experiments (six
mice per group).423 Marinaro et al.
employed the delivery of this regulatory cytokine either by
a parenteral (i.p.) or by the same (oral) route as antigen and
CT adjuvant.
Increasing doses of rmIL-12 given i.p. progressively sup-
pressed systemic IgE and IgG1 responses, further, this was
accompanied by enhanced IgG2a Abs to TT given orally
with the adjuvant CT. This finding added support to previ-
ous observations that the administration schedule (dose and
frequency) of IL-12 during the period of antigen-induced
immune stimulation is critical for induction of maximum
effects in vivo (15, 42) and that IL-12 can inhibit both in
vitro (27) and in vivo (28) production of IgE Abs. How-
ever, past work on the role of IL-12 on serum IgG sub-
classes yielded conflicting results (15, 28–30). In this regard,
mice injected with anti-IgD Abs exhibited inhibition of
IgG1, IgG2a and IgG3 subclasses after IL-12 treatment
(15), while coadministration of IL-12 to mice immunized
with haptenated-protein markedly inhibited IgG1, but was
without effect on other IgG subclasses (29). In contrast,
others have observed enhanced IgG2a Ab responses to hen
egg white lysozyme (30) as well as IgG2a, IgG2b, and IgG3
Ab responses to several protein antigens (28). The finding
that parenteral administration of rmIL-12 (100 ng/dose)
during the initiation of immune responses to an oral vac-
cine significantly enhanced IgG2a and IgG3 and downreg-
ulated IgG1 Abs are consistent with the fact that IL-12 in-
duces IFN-g production which would support Th1-type
cell differentiation with specific help for IgG2a and IgG3
Ab responses (23, 24, 26). Differences in antigen and poly-
clonal stimulation systems and in IL-12 administration
schedules used in previous studies could explain the differ-
ences observed for IgG subclass responses.
The finding that oral delivery of rmIL-12 induced simi-
lar regulatory effects on serum IgE and IgG subclass Ab re-
sponses suggested that this cytokine could be efficiently de-
livered to mucosal inductive sites, i.e., the PP. To our
knowledge this is the first evidence that IL-12 can resist en-
zymatic degradation in the GI tract and exert a regulatory
effect on systemic immune responses to an oral vaccine. In
support of this observation, previous reports have shown
that hormones (46–49) and interferons (a and b) (50–52)
retain biological activity after oral administration even in
the absence of detectable levels of these molecules in se-
rum. In addition, in a separate study we have observed that
PP are the major site of rmIL-12–liposome uptake in the
GI tract after oral delivery and that increased expression of
Ly6A/E occurred on PP lymphocytes after oral administra-
tion of rIL-12–liposomes (Marinaro M., P.N. Boyaka, R.J.
Jackson, F.D. Finkelman, H. Kiyono, E. Jirillo, and J.R.
McGhee, manuscript in preparation). This was consistent
with the findings of others which showed that oral delivery
of liposomes to rats led to a preferential uptake by PP (53).
Further, M cells in the epithelium overlying PP promoted
the passage of liposomes to underlying lymphoid cells (54).
Of particular interest was the finding that the numbers of
IgA antibody-forming cells (AFC) in the lamina propria of
the small intestine as well as IgA Ab titers in fecal extracts
were not affected by oral administration of IL-12 in con-
trast to parenterally administered cytokine which did re-
duce the levels of specific mucosal IgA responses. This
finding suggested that differences occur in the ability of
orally versus parenterally administered rmIL-12 to regulate
mucosal IgA responses. It has been shown that mucosal IgA
responses are optimally induced by Th2-type cell-derived
cytokines, e.g., IL-4, IL-5, IL-6, and IL-10 (36, 37, 55–57).
Furthermore, IL-4-deficient mice and IL-6-deficient mice
exhibited impaired mucosal immunity (32, 35, 41, 57). Al-
though oral delivery of rmIL-12–liposomes resulted in the
induction of TT-specific CD41 T cells producing IFN-g
and IL-2, we also found that significant production of se-
lect Th2-type cytokines still occurred. Thus, stimulated
CD41 T cells secreted IL-5, IL-6, and IL-10, while insig-
nificant levels of IL-4 were present. On the other hand,
parenteral administration of IL-12 profoundly suppressed
Th2-type cytokines. Thus, we propose that maintenance of
S-IgA Ab responses when IL-12 was delivered orally was
due to the presence of TT-specific CD41 T cells which
produce select Th2-type cytokines. In support of this, se-
rum IL-5 and IL-10 levels were also higher in mice receiv-
ing oral versus parenteral IL-12, confirming that these cy-
tokines were maintained at higher levels in vivo. Thus, the
S-IgA Ab response following oral treatment with IL-12–
liposomes was most likely due to the presence of CD41
T cells producing IL-5, IL-6, and IL-10, which provided
effective help for this isotype. In this regard, IL-6 has been
shown to be the most efficient terminal differentiation fac-
tor for murine IgA committed B cells to become IgA se-
creting plasma cells (56, 57) and both IL-5 and IL-10 have
also been associated with IgA responses in experimental an-
imals (55, 58) and in humans (59).
The lack of suppression of Th2-type cytokines both in vi-
tro and in vivo induced by oral IL-12–liposomes concomi-
Figure 7. Induction of delayed-type hypersensitivity responses in
rmIL-12–treated mice given the combined oral vaccine. Three groups of
mice were assessed and included combined oral vaccine only (unshaded),
those receiving combined oral vaccine and rmIL-12 by the i.p. (striped; 15
times 100 ng/dose) route, or mice given rmIL-12 by the oral route
(shaded; six times 1,000 ng/dose). The results are expressed as the mean 6
one SD of the difference in the ear swelling between the TT-injected and
OVA-injected ear pinna and are representative of three separate experi-
ments.424 Oral IL-12 Redirects Th2®Th1 with IgA Responses
tant with a normal mucosal IgA response are in contrast with
the finding that the oral route of rmIL-12 delivery induced
major effects on systemic Ab responses. To further investi-
gate possible mechanisms whereby oral rmIL-12–liposomes
induced systemic regulatory effects, we measured serum
IL-12 levels after oral or parenteral administration. Oral de-
livery of IL-12 increased serum IL-12 to a much lesser ex-
tent than did parenteral delivery. This implies that the ac-
tivity of oral IL-12 was more likely due to initial effects on
lymphoid cells in the mucosal immune compartment rather
than to passage of cytokine into the blood circulation.
Since it has been shown that PP dendritic cells can stimu-
late CD41 T cells with an increased propensity to support
IgA synthesis (60, 61), it was possible that IFN-g synthesis
after oral rmIL-12–liposome administration may result in
the activation of mucosal dendritic cells with subsequent in-
duction of selected cytokines (e.g., IL-5 and IL-6) for sup-
port of IgA production.
Further support for direct effects of rmIL-12 in the PP or
gut-associated lymphoreticular tissue (GALT) was the find-
ing that IgE responses were essentially abrogated by oral
administration of six doses of rmIL-12 liposomes. Further-
more, IgE responses were markedly down regulated after
administration of only three oral doses of rmIL-12–lipo-
somes. Indeed, it has been suggested that IgE-specific B cells
arise in GALT, irregardless of the route of immunization
(62). In that study, surface IgE-positive (sIgE1) B cells and
hapten-specific IgE AFC were analyzed during an immune
response to benzylpenicilloyl keyhole limpet hemocyanin
administered by several routes (i.p., gavage, intravenous,
subcutaneous, and intramuscular) with aluminum hydrox-
ide adjuvant. It was found that commitment of murine B
cells to express IgE (sIgE1) first occurred in PP with subse-
quent differentiation of sIgE1 B cells into IgE AFC (62).
Our results suggest that uptake of IL-12 by PP results in the
induction of CD41 T cells producing IFN-g which sup-
pressed IgE secretion by downregulating IL-4 production
(22–24, 26). The targeted delivery of IL-12 with induction
of IFN-g to the site where IgE responses arise (i.e., the PP)
may explain the substantial downregulation of IgE Abs
which occurs following oral administration of IL-12.
The finding that serum IFN-g levels measured in mice
receiving the oral vaccine and either oral or parenteral IL-12
differed in magnitude also merits discussion. We found that
both splenic and PP CD41 T cells from mice receiving
either oral or parenteral rmIL-12 secreted comparable
amounts of IFN-g after antigenic stimulation in vitro.
Thus, although the potential of antigen-specific T cells to
produce IFN-g was similar in both groups of mice, differ-
ences in serum IFN-g levels were related to the different
administration schedules. In this regard, we have shown
that increasing doses of IL-12 delivered parenterally not
only increased the total amount of this cytokine in the se-
rum but also prolonged survival in the circulation. Thus, a
longer persistence of IL-12 in the sera together with the
different timing of administration could be responsible for
the higher levels of IFN-g detected in the sera of mice re-
ceiving parenteral IL-12 during the immunization pro-
tocol.
In summary, our study has provided the first evidence
that IL-12 can be administered by the oral route for regula-
tion of systemic immune responses to an oral vaccine and
suggests that oral IL-12 can also exert immunomodulatory
effects at the mucosal level. This latter finding has impor-
tant implications for the targeted induction of immune re-
sponses to mucosal vaccines. Furthermore, the differential
effect of oral versus parenteral IL-12 on S-IgA Ab responses
also emphasizes the unique features of the mucosal and sys-
temic immune compartments, respectively. Whether mu-
cosal as well as parenteral immune responses to mucosal
vaccines can be manipulated by delivering IL-12 or other
cytokines through additional mucosal routes is currently
under investigation.
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